Given this conflicting data, and the fact that hitherto only one publication probing Lyn activation in large scale clinical samples using American dataset REMBRANDT [40], our data fills a lack of knowledge and promotes Lyn to serve a clinical relevant therapeutic target in glioma. This evidence concerns the gene LYN and glioma.